Background illustration for clinical trials search

Paid Clinical Trials Birmingham

Discover 889 paid clinical trials in Birmingham, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 889

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

for

Muscle Invasive Bladder Urothelial Carcinoma,

Location: Birmingham AL, Newnan GA, Germantown TN, Jackson MS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT07061964

Phase2, Recruiting

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

for

Core Binding Factor Acute Myeloid Leukemia

Location: Birmingham AL, Columbus MS, New Albany MS, Oxford MS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT06917911

Phase2, Recruiting

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

for

Endometrial Adenocarcinoma,

Location: Birmingham AL, Augusta GA, Louisville KY, Effingham IL,

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05112601

Phase2, Recruiting

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for

Pancreatic Neoplasm

Location: Birmingham AL, Atlanta GA, Nashville TN, Mobile AL,

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 50 - 70+

Code: NCT04239573

Recruiting

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

for

Recurrent Non-Muscle Invasive Bladder Carcinoma,

Location: Birmingham AL, Metairie LA, Gainesville FL,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT07000084

Phase3, Recruiting

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

for

Castration-Resistant Prostate Carcinoma,

Location: Birmingham AL, Greer SC, Spartanburg SC, Union SC,

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All

Age: 18+

Code: NCT06632977

Phase2, Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

for

Advanced Malignant Solid Neoplasm,

Location: Birmingham AL, Columbus MS, New Albany MS, Oxford MS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0+

Code: NCT05564377

Phase2, Recruiting

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for

Metastatic Clear Cell Renal Cell Carcinoma,

Location: Birmingham AL, Gulfport MS, Cape Girardeau MO,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04510597

Phase3, Recruiting

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia,

Location: Birmingham AL, Columbus MS, New Albany MS, Oxford MS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554406

Phase2, Recruiting

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

for

Malignant Solid Neoplasm

Location: Birmingham AL, Atlanta GA, Hendersonville NC, Greer SC,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05642611

Phase3, Recruiting

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Birmingham AL, Columbus MS, New Albany MS, Oxford MS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 59

Code: NCT05554393

Phase2, Recruiting

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

for

Ovarian Cancer

Location: Birmingham AL

Sponsor: University of Alabama at Birmingham

Sex: Female

Age: 18+

Code: NCT05952453

Phase2, Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

for

Multiple Myeloma

Location: Birmingham AL, Baltimore MD, Toronto, New York NY,

Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT05372354

Phase1, Phase2, Recruiting

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

for

Neoplasms, Brain, Glioblastoma Multiforme,

Location: Birmingham AL, St Louis MO, Houston TX

Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 3 - 22

Code: NCT03911388

Phase1, Recruiting

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for

Ovarian Carcinoma

Location: Birmingham AL, Atlanta GA, Decatur GA, Franklin TN,

Sponsor: NRG Oncology

Sex: Female

Age: 35 - 50

Code: NCT04251052

Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

for

Acute Myeloid Leukemia

Location: Birmingham AL, Columbus MS, New Albany MS, Oxford MS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06317649

Phase2, Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for

Classic Follicular Lymphoma,

Location: Birmingham AL, Atlanta GA, Memphis TN, Southhaven MS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06337318

Phase3, Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for

Acute Myeloid Leukemia,

Location: Birmingham AL, Columbus MS, New Albany MS, Oxford MS,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05564390

Phase2, Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

for

Acral Lentiginous Melanoma,

Location: Birmingham AL, Mobile AL, Fairhope AL, Paducah KY,

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT04511013

Phase2, Recruiting

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8,

Location: Birmingham AL, Tuscaloosa AL, Atlanta GA, Decatur GA,

Sponsor: NRG Oncology

Sex: Male

Age: 18+

Code: NCT05946213

Phase3, Recruiting

Paid Clinical Trials Birmingham

Filter results

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Interested in new trials?

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer